Nivolumab + ipilimumab (melanoma, 1L metastatic)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-NIVOLUMAB` `DRUG-IPILIMUMAB`

ID	`REG-NIVO-IPI-MELANOMA`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MELANOMA-2024` `SRC-NCCN-MELANOMA-2025`

Notes

CheckMate-067 7.5y OS 49%. Higher ipi dose (3 mg/kg) than RCC (1 mg/kg).

Used By

Handbook Chapters

HB-MELANOMA-METASTATIC-1L - Metastatic melanoma: BRAF / IO first-line reasoning

Handbook Questions

HQ-MELANOMA-MET-1L-001 - HQ-MELANOMA-MET-1L-001

Indication

IND-MELANOMA-2L-POST-BRAFI-IPI-NIVO - IND-MELANOMA-2L-POST-BRAFI-IPI-NIVO
IND-MELANOMA-METASTATIC-1L-NIVO-IPI - IND-MELANOMA-METASTATIC-1L-NIVO-IPI

Regimen

REG-IPI-NIVO-ESOPH-SCC - Nivolumab + ipilimumab (ESCC, 1L metastatic; CheckMate-648)